US focuses pharma supply chain scrutiny

The US Food and Drug Administration (FDA) has named 13 companies that will be allowed to import drug products into the US with reduced scrutiny. Each company will be permitted to import up to five products under expedited entry arrangements for a period of two years.

The FDA’s Secure Supply Chain Pilot Program is an effort to free up the agency’s resources to focus on areas where imports pose the greatest risk to patients and consumers. The scheme rewards manufacturers for voluntarily adopting best practice and integrating integrity and security into their supply chain operations.

The move comes in the wake of a string of product recalls and import bans as some elements of the pharma industry struggle to maintain appropriate quality standards.

Related Content

Reaching out

22 May 2014 Premium contentFeature

news image

Andy Extance surveys how pharma uses outsourcing in a variety of different ways

Indian pharma under increased regulatory scrutiny

21 August 2015 Business

news image

Import bans and tightened rules pose a significant challenge for companies

Most Commented

How do we solve a problem like Marie?

21 May 2015 The Crucible

news image

Women in science’s history deserve better treatment than myths and martyrdom, says Philip Ball

Chemistry at heart of VW emissions cheating

28 September 2015 News and Analysis

news image

Car firm dodged nitrogen oxide pollution limits using software that detected testing